XNK appreciates that partnerships and collaboration are essential components of the continuous development and learning required to stay ahead in the natural killer (NK) cell therapy field. Partnerships bring new ideas, additional capabilities and valuable experience for the benefit of patients. To complement our in-house scientific and clinical expertise, XNK is actively collaborating with the Karolinska Institute and the Karolinska University Hospital in both preclinical and clinical stage projects. XNK is also collaborating with other pharmaceutical companies, such as Sanofi, to evaluate the combination of evencaleucel with the CD38 mAb isatuximab.
XNK is always open to discuss interesting R&D and/or commercial collaborative opportunities.